我們已在上線! 進一步了解
CNC圖示

Centene

69.16 USD
-1.35
1.91%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
69.40
+0.24
0.35%
1天
-1.91%
5天
5.43%
1個月
4.77%
3個月
8.25%
6個月
77.33%
今年迄今
65.53%
1年
94.05%
5年
8.05%
10年
131.54%
 

關於: Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.

員工: 61,100

新聞

正面
中性
負面
市場情緒 3個月
正面 70.5%
中性 23.8%
負面 5.7%
中性
PRNewsWire
14 小時前
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
Expansion into Ohio and Oklahoma for plan year 2027 builds on early success offering employees  CHOICE Arrangements in Indiana in 2026 ST. LOUIS, Oct. 16, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced the expansion of its CHOICE Arrangements benefit program (formerly ICHRA) to employees in Ohio and Oklahoma for plan year 2027.
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
正面
Seeking Alpha
昨天
Centene: The Turnaround Has More Room To Run
Centene Corp. maintains a Buy rating as profitability recovers faster than expected, with Q2 2026 adjusted EPS of $2.51 versus a prior-year loss. CNC raised full-year adjusted EPS guidance to over $4.80, driven by improved Marketplace and Medicare Part D margins, despite a 40% YoY decline in Marketplace membership. Medicaid remains a headwind, with expected 8–9% membership decline in 2026 and regulatory risks from OB3, but management targets margin improvement and breakeven Medicare Advantage in 2027.
Centene: The Turnaround Has More Room To Run
正面
Seeking Alpha
昨天
Centene Remains A Buy Heading Into Q3
Centene Corporation remains a Buy, supported by operational improvements, disciplined capital management, and a discounted valuation versus sector averages. CNC's Medicaid margins are holding up despite expected 8–9% membership attrition, aided by favorable rate adjustments and strong medical cost control. Medicare segment profitability is improving, with prescription drug plan margins now expected to be above 3% for the year, up from 2%.
Centene Remains A Buy Heading Into Q3
中性
Zacks Investment Research
前天
Centene's Gold Card Push Could Ease Costs - But Will Savings Follow?
Centene's nationwide Gold Card program aims to streamline prior authorization and cut administrative costs, but adoption and actual savings will determine its financial impact.
Centene's Gold Card Push Could Ease Costs - But Will Savings Follow?
中性
PRNewsWire
3 天前
PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
MECHANICSBURG, Pa., Oct. 13, 2026 /PRNewswire/ -- PA Health & Wellness, a leading managed care organization in Pennsylvania and a company of Centene Corporation (NYSE: CNC), today announced that it has been recognized among the top 17 Medicaid health plans in the United States by the National Committee for Quality Assurance (NCQA) for the second consecutive year.
PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
中性
PRNewsWire
3 天前
Centene to Launch Nationwide Gold Card Program for Qualifying Providers
ST. LOUIS, Oct. 13, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced it will launch its National Performance-Based Gold Card Program in November 2026. The program, which will initially be available to more than 160,000 qualifying providers nationwide for select outpatient services, is designed to streamline the prior authorization review process while maintaining appropriate clinical and quality standards.
Centene to Launch Nationwide Gold Card Program for Qualifying Providers
正面
Zacks Investment Research
4 天前
Centene vs. Molina: Which Managed Care Stock Has More Upside?
CNC's diversified business, improving margins and lower valuation give it an edge over MOH, with stronger earnings prospects and greater upside potential.
Centene vs. Molina: Which Managed Care Stock Has More Upside?
正面
Seeking Alpha
6 天前
Centene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not
Centene Corporation has rebounded sharply, with shares up 73% in a year, but now trades near fair value. I expect a Q3 adjusted EPS beat (~$0.25 vs. $0.07–$0.10 consensus), but I see limited upside as 2027 earnings normalization remains the key debate. Medicaid improvement is crucial; HBR progress and membership declines must be closely monitored as policy risks and cost trends remain material.
Centene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not
正面
Zacks Investment Research
9 天前
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
CNC's improving Medicaid margins, stronger Marketplace profitability and earnings recovery support its valuation, but sustainability remains the key test.
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
中性
PRNewsWire
9 天前
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
The new partnership will provide eligible members with $0 primary care visits, lab services, and virtual care beginning in 2027 ST. LOUIS, Oct. 7, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), through Ambetter Health Solutions, today announced a new collaboration with Marathon Health, a leading advanced primary care provider, designed to make primary care easier to access for Ambetter members in select counties across Indiana and Missouri.
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
價格圖表採用Lightweight Charts™實作